vs
Side-by-side financial comparison of IM Cannabis Corp. (IMCC) and Regencell Bioscience Holdings Ltd (RGC). Click either name above to swap in a different company.
IM Cannabis Corp is a global cannabis enterprise focused on the cultivation, production, distribution and retail of medical and adult-use cannabis products. It runs business across core markets including North America, the European Union and Israel, offering branded cannabis goods, wellness derivatives and related consumer products to medical patients and recreational users.
Regencell Bioscience Holdings Ltd is a specialized bioscience enterprise focused on the research, development and commercialization of therapeutic products derived from traditional Chinese medicine. Its core pipeline targets neurodegenerative, immunological and infectious disease treatments, with primary operating markets across Greater China and other Asian regions.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $10.1K | — | ||
| Q2 25 | $8.8K | — | ||
| Q4 24 | $11.8K | — | ||
| Q3 24 | $9.0K | — | ||
| Q2 24 | $10.8M | — | ||
| Q1 24 | $9.1K | — |
| Q3 25 | $-790 | — | ||
| Q2 25 | $-4.4K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.6K | — | ||
| Q2 24 | $-2.5M | — | ||
| Q1 24 | — | — |
| Q3 25 | 22.7% | — | ||
| Q2 25 | 14.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.4% | — | ||
| Q2 24 | 5.7% | — | ||
| Q1 24 | 23.2% | — |
| Q3 25 | -6.9% | — | ||
| Q2 25 | -46.7% | — | ||
| Q4 24 | -236.7% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | -19.5% | — | ||
| Q1 24 | 28.9% | — |
| Q3 25 | -7.8% | — | ||
| Q2 25 | -49.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -17.3% | — | ||
| Q2 24 | -23.4% | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
